Search Results - Ariane Dubost-Brama

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis by Michael J. Cork, Diamant Thaçi, Lawrence F. Eichenfield, Peter D. Arkwright, Zhen Chen, Ryan B. Thomas, Matthew P. Kosloski, Ariane Dubost-Brama, Randy Prescilla, Ashish Bansal, Noah A. Levit

Connect to this object online.

Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)Capsule Summary by Gil Yosipovitch, MD, Brian S. Kim, MD, Shawn G. Kwatra, MD, Nicholas K. Mollanazar, MD, Sonja Ständer, MD, Takahiro Satoh, MD, PhD, Pedro Mendes-Bastos, MD, Tsen-Fang Tsai, MD, Elizabeth Laws, PhD, Michael C. Nivens, PhD, Jennifer Maloney, MD, Genming Shi, PhD, Ashish Bansal, MD, MBA, Ariane Dubost-Brama, MD

Connect to this object online.